| Most likely to benefit from immunoprophylaxis: |
| Infants <12 months of age with acyanotic heart disease who are receiving medication to control heart failure and will require cardiac surgery |
| Infants <12 months of age with moderate to severe pulmonary hypertension |
| May benefit from immunoprophylaxis: |
| Infants <12 months of age with cyanotic heart disease |
| Children younger than 2 years who undergo cardiac transplantation during RSV season |
| Not indicated: |
| Children ≥12 months (with the exception of those <2 years undergoing cardiac transplantation during RSV season) |
| Infants <12 months with hemodynamically insignificant heart disease: |
| Secundum atrial septal defect |
| Small ventricular septal defect |
| Pulmonic stenosis |
| Uncomplicated aortic stenosis |
| Mild coarctation of the aorta |
| Patent ductus arteriosus |
| Infants <12 months of age with lesions adequately corrected by surgery unless they continue to require medication |
| Infants <12 months of age with mild cardiomyopathy who are not receiving medical therapy |
